. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: J Affect Disord. 2018 Feb 27;234:34–37. doi: 10.1016/j.jad.2018.02.089

Table 1.

Likelihood of remission based on pre-treatment BMI categories during the acute-phase of CO-MED trial (n=662)

	Odds Ratio	95% CI
Normal- or under-weight (BMI <25)
SSRI monotherapy vs. Bupropion-SSRI combination	1.92	0.83, 4.46
Venlafaxine-mirtazapine vs. Bupropion-SSRI combination	2.49	1.07, 5.78
Overweight (BMI 25–29.9)
SSRI monotherapy vs. Bupropion-SSRI combination	1.09	0.53, 2.25
Venlafaxine-mirtazapine vs. Bupropion-SSRI combination	0.75	0.35, 1.59
Obese I (BMI 30–34.9)
SSRI monotherapy vs. Bupropion-SSRI combination	1.23	0.51, 2.98
Venlafaxine-mirtazapine vs. Bupropion-SSRI combination	0.71	0.30, 1.65
Obese II+ (BMI ≥35)
SSRI monotherapy vs. Bupropion-SSRI combination	0.38	0.17, 0.83
Venlafaxine-mirtazapine vs. Bupropion-SSRI combination	0.75	0.34, 1.68

BMI is body mass index, CI is confidence interval, SSRI is selective serotonin reuptake inhibitor. The three treatment arms in Combining Medications to Enhance Depression Outcomes (CO-MED) trial included escitalopram plus placebo (SSRI monotherapy), sustained release bupropion plus escitalopram (bupropion-SSRI combination), and extended-release venlafaxine plus mirtazapine (venlafaxine-mirtazapine combination). Bolded odds ratio values indicate statistically significant findings as the 95% CI does not include 1.00.